Important molecular diagnostic markers, such as isocitrate dehydrogenase (IDH) mutation,83 1p/19q co-deletion84 and O-6-methylguanine-DNA methyltransferase promoter methylation,85 had been included into guideline since WHO glioma classification 2016.80 Here, IDH3A is linked to central nervous system cancer.